Imaging Tumor Necrosis with Ferumoxytol Maryam Aghighi1, Daniel Golovko2, Celina Ansari1, Neyssa M. Marina1, Laura Pisani1, Lonnie Kurlander1, Christopher Klenk1, Srabani Bhaumik3, Michael Wendland4, Heike E. Daldrup-Link1* 1 Department of Radiology, Molecular Imaging Program at Stanford, Stanford University, Stanford, CA, United States of America, 2 School of Medicine, Tufts University, Medford, MA, United States of America, 3 GE Global Research Center, Research Circle, Niskayuna, NY, United States of America, 4 University of California, Berkeley, CA, United States of America * [email protected]

Abstract Objective

OPEN ACCESS Citation: Aghighi M, Golovko D, Ansari C, Marina NM, Pisani L, Kurlander L, et al. (2015) Imaging Tumor Necrosis with Ferumoxytol. PLoS ONE 10(11): e0142665. doi:10.1371/journal.pone.0142665 Editor: Efstathios Karathanasis, Case Western Reserve University, UNITED STATES

Ultra-small superparamagnetic iron oxide nanoparticles (USPIO) are promising contrast agents for magnetic resonance imaging (MRI). USPIO mediated proton relaxation rate enhancement is strongly dependent on compartmentalization of the agent and can vary depending on their intracellular or extracellular location in the tumor microenvironment. We compared the T1- and T2-enhancement pattern of intracellular and extracellular USPIO in mouse models of cancer and pilot data from patients. A better understanding of these MR signal effects will enable non-invasive characterizations of the composition of the tumor microenvironment.

Received: July 11, 2015

Materials and Methods

Accepted: October 26, 2015

Six 4T1 and six MMTV-PyMT mammary tumors were grown in mice and imaged with ferumoxytol-enhanced MRI. R1 relaxation rates were calculated for different tumor types and different tumor areas and compared with histology. The transendothelial leakage rate of ferumoxytol was obtained by our measured relaxivity of ferumoxytol and compared between different tumor types, using a t-test. Additionally, 3 patients with malignant sarcomas were imaged with ferumoxytol-enhanced MRI. T1- and T2-enhancement patterns were compared with histopathology in a descriptive manner as a proof of concept for clinical translation of our observations.

Published: November 16, 2015 Copyright: © 2015 Aghighi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Data Availability Statement: All relevant data are within the paper. Funding: The authors acknowledge support from the National Cancer Institute, grant number R21CA176519 and the Eunice Kennedy Shriver National Institute for Child Health and Human Development, grant number R01-HD081123. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Competing Interests: The authors have declared that no competing interests exist.

Results 4T1 tumors showed central areas of high signal on T1 and low signal on T2 weighted MR images, which corresponded to extracellular nanoparticles in a necrotic core on histopathology. MMTV-PyMT tumors showed little change on T1 but decreased signal on T2 weighted images, which correlated to compartmentalized nanoparticles in tumor associated macrophages. Only 4T1 tumors demonstrated significantly increased R1 relaxation rates of the tumor core compared to the tumor periphery (p

Imaging Tumor Necrosis with Ferumoxytol.

Ultra-small superparamagnetic iron oxide nanoparticles (USPIO) are promising contrast agents for magnetic resonance imaging (MRI). USPIO mediated prot...
NAN Sizes 1 Downloads 9 Views

Recommend Documents

Ferumoxytol-Enhanced Magnetic Resonance Imaging in Late-Stage CKD.
Ferumoxytol is a superparamagnetic iron oxide particle encapsulated by a semisynthetic carbohydrate with properties that can be used by the nephrologist for diagnosis and therapy. Ferumoxytol is approved by the US Food and Drug Administration for tre

Tumor necrosis factor, tumor necrosis factor inhibition, and cancer risk.
Tumor necrosis factor (TNF) is a highly pleiotropic cytokine with multiple activities other than its originally discovered role of tumor necrosis in rodents. TNF is now understood to play a contextual role in driving either tumor elimination or promo

Feasibility of islet magnetic resonance imaging using ferumoxytol in intraportal islet transplantation.
There is a clinical need for an alternative labeling agent for magnetic resonance imaging (MRI) in islet transplantation. We aimed to evaluate the feasibility of islet MRI using ferumoxytol, which is the only clinically-available ultrasmall superpara

Novel strategies to mimic transmembrane tumor necrosis factor-dependent activation of tumor necrosis factor receptor 2.
Tumor necrosis factor receptor 2 (TNFR2) is known to mediate immune suppression and tissue regeneration. Interestingly, the transmembrane form of tumor necrosis factor (tmTNF) is necessary to robustly activate TNFR2. To characterize the stoichiometry

Pre-clinical Evaluation of a Cyanine-Based SPECT Probe for Multimodal Tumor Necrosis Imaging.
Recently we showed that a number of carboxylated near-infrared fluorescent (NIRF) cyanine dyes possess strong necrosis avid properties in vitro as well as in different mouse models of spontaneous and therapy-induced tumor necrosis, indicating their p

Evaluation of pseudoprogression in patients with glioblastoma multiforme using dynamic magnetic resonance imaging with ferumoxytol calls RANO criteria into question.
Diagnosis of pseudoprogression in patients with glioblastoma multiforme (GBM) is limited by Response Assessment in Neuro-Oncology (RANO) criteria to 3 months after chemoradiotherapy (CRT). Frequency of pseudoprogression occurring beyond this time lim

Tumor necrosis on magnetic resonance imaging correlates with aggressive histology and disease progression in clear cell renal cell carcinoma.
The study objective was to correlate the magnetic resonance imaging (MRI) features of clear cell renal cell carcinoma (ccRCC) with the histopathologic features and disease progression.

Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy.
With the success of ipilimumab and promise of programmed death-1 pathway-targeted agents, the field of tumor immunotherapy is expanding rapidly. Newer targets for clinical development include select members of the tumor necrosis factor receptor (TNFR

Ferumoxytol-enhanced magnetic resonance imaging methodology and normal values at 1.5 and 3T.
Ultrasmall superparamagnetic particles of iron oxide (USPIO)-enhanced magnetic resonance imaging (MRI) can detect tissue-resident macrophage activity and identify cellular inflammation. Clinical studies using this technique are now emerging. We aimed